Opinion statementPrazosin is a generically available central nervous system (CNS) active alpha-1 adrenoreceptor antagonist that has been demonstrated effective in randomized controlled trials (RCTs) for posttraumatic stress disorder (PTSD) trauma nightmares, distressed awakenings, daytime hyperarousal symptoms, and global clinical function. The contribution of increased CNS noradrenergic activity to PTSD pathophysiology and the involvement of the postsynaptic alpha-1 adrenoreceptor in brain systems relevant to PTSD symptomatology provide neurobiologic rationale for prazosin as a PTSD pharmacotherapeutic. This article reviews the clinical observations that led to the development of prazosin therapy for PTSD in combat veterans and the subsequent RCTs that demonstrated prazosin efficacy.
IntroductionPosttraumatic stress disorder (PTSD) encompasses clusters of symptoms that follow exposure to one or more major traumatic events. The four PTSD symptom clusters include intrusion (or reexperiencing), avoidance, negative alterations in c o g n i t i o n a n d m o o d a s s o c i a t e d w i t h t h e trauma(s), and hyperarousal. The phenomenologic features of several major PTSD hyperarousal symptoms including sleep disturbance (particularly distressed awakenings), hypervigilance, irritability/low anger threshold, and trauma nightmares, particularly when associated with sweating, tachycardia, and other manifestations of autonomic arousal, suggest that increased noradrenergic outflow and/ or postsynaptic adrenoreceptor (AR) responsiveness to norepinephrine (NE) contribute to their pathophysiology [1]. Increased central nervous system (CNS) noradrenergic activity in PTSD is supported by multiple clinical studies [2][3][4][5][6]. Therefore, reducing CNS noradrenergic activity is a rational therapeutic strategy when distressing trauma nightmares and hyperarousal symptoms are major components of the patient's clinical presentation. This article focuses on the pharmacotherapeutic strategy of reducing CNS postsynaptic responsiveness in PTSD using the alpha-1 AR antagonist prazosin. Among the clinically available alpha-1 ARs, prazosin is the most lipid soluble and therefore crosses the periphery into the CNS most easily [7].